To see the other types of publications on this topic, follow the link: Garcia Sanchez.
Journal articles on the topic 'Garcia Sanchez'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Garcia Sanchez.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Froberg, Ralf. "J.C. Rosales, P.A. Garcia-Sanchez: Numerical Semigroups." Semigroup Forum 81, no. 3 (May 7, 2010): 555–57. http://dx.doi.org/10.1007/s00233-010-9229-y.
Full text
2
Silva, Carlos Guardado da. "[Recensão a] GARCÍA SANCHEZ, J. ; GARCIA SANCHEZ, J. ; GARCIA SANCHEZ, J. (2016) - El heroísmo mirobrigense de 1808 a 1810: La historia contada por sus habitantes: hechos relevantes, incidentes destacados y personas ilustres. Salamanca." Boletim do Arquivo da Universidade de Coimbra 33, no. 2 (November 13, 2020): 111–15. http://dx.doi.org/10.14195/2182-7974_33-2_5.
Full text
3
Garcia, M. C., M. G. López, A. G. Garcia, and M. Sánchez Crespo. "REPLY FROM M.C. GARCIA, M. G. LOPEZ, A. G. GARCIA, AND M. SANCHEZ CRESPO." Journal of Neurochemistry 60, no. 5 (May 1993): 1979–80. http://dx.doi.org/10.1111/j.1471-4159.1993.tb13436.x.
Full text
4
Greenfield, Sumner M., Miguel Garcia-Posada, and Federico Garcia Lorca. "Federico Garcia Lorca, Primer romancero gitano/Llanto por Ignacio Sanchez Mejias." Hispanic Review 59, no. 2 (1991): 249. http://dx.doi.org/10.2307/473744.
Full text
5
Cate-Arries, Francie, Andrew Anderson, and Federico Garcia Lorca. "Federico Garcia Lorca, Divan del Tamarit / Seis poemas galegos / Llanto por Ignacio Sanchez Mejias / Poemas sueltos." Hispanic Review 61, no. 1 (1993): 114. http://dx.doi.org/10.2307/473303.
Full text
6
Quealy-Gainer, Kate. "Death, Dickinson, and the Demented Life of Frenchie Garcia by Jenny Torres Sanchez (review)." Bulletin of the Center for Children's Books 66, no. 11 (2013): 531. http://dx.doi.org/10.1353/bcc.2013.0441.
Full text
7
Grohe, J. "Synodicon Hispanum, hg. v. A. Garcia y Garcia IV: Ciudad Rodrigo, Salamanca y Zamora, v. B. Alonso Rodriguez, F.R. Aznar Gil, F. Cantelar Rodriguez, A. Garcia Y Garcia, J. Sanchez Herrero, Madrid 1987. XX, 474 S./V: Extremadura: Badajoz, Coria-Caceres y Plasencia, v. B. Alonso Rodriguez, F. Cantelar Rodriguez, A. Garcia Y Garcia, J.L. Martin Martin, J.C. Matias Vicente, C. Perez Coca Y Sanchez Mata, Madrid 1990. XIX, 570 S." Annarium Historiae Conciliorum 23, no. 1-2 (February 16, 1991): 398–401. http://dx.doi.org/10.30965/25890433-0230102008.
Full text
8
Herianti, Eva, Arna Suryani, and Amor Marundha. "Managerial Ability and Future Banking Performance: The Role of Book-Tax Differences as Moderator." Journal of Accounting and Investment 22, no. 1 (January 4, 2021): 173–91. http://dx.doi.org/10.18196/jai.v22i1.9997.
Full textAbstract:
Research aims: This study aims to examine and analyze the effect of managerial ability on future banking performance moderated by book-tax differences.Design/Methodology/Approach: The research samples were banks listed on the Indonesia Stock Exchange from 2014 to 2018. A purposive sampling technique was conducted to collect 108 samples of future banking performance (t+1) and 81 samples of future banking performance (t+2). The data were then analyzed using eviews version 10 with the ordinary least square.Research findings: The results showed that managerial ability positively and significantly affected future banking performance (t+1 and t+2), while book-tax differences could reduce the effect of managerial ability on future banking performance (t+1 and t+2).Theoretical contribution/Originality: This study has provided implications to the literature that managers use their abilities to achieve sustainable competitive advantage through efficient and effective use of resources. Managers need an understanding of the relationship between resources, their abilities, competitive advantages, and future earnings achievement.Practitioner/Policy implication: Since managerial ability can increase future banking performance, this study’s results may affect how companies produce managerial ability through efficient use of inputs to produce optimal output that is useful for long-term banking performance.Research limitation/Implication: The conclusion is drawn based on various proxies to measure the managerial ability, book-tax differences, and future banking performance. Further research can develop the managerial ability proxies besides those proposed by Garcia-meca Garcia-Sanchez (2018).
9
Tejedor-Martinez, C. "Daniel Molina Garcia and Francisco Sanchez Benedito. Analisis del Diccionario Nuevo de las Dos Lenguas Espanola e Inglesa de Connelly & Higgins (1797-1798)." International Journal of Lexicography 25, no. 3 (May 21, 2012): 371–74. http://dx.doi.org/10.1093/ijl/ecs005.
Full text
10
Evans, G. R. "Alfonso do Madrigal, el Tostado: Introduccion al Evangelio segun San Mateo. Edited by JOSE MANUEL SANCHEZ CARO, ROSA MARIA HERRERA GARCIA, and INMACULADA DELGADO JARA." Journal of Theological Studies 61, no. 1 (February 15, 2010): 400–401. http://dx.doi.org/10.1093/jts/flq014.
Full text
11
Fernández-Díaz, C., S. Castañeda, R. Melero, J. Loricera, F. Ortiz-Sanjuán, A. Juan-Mas, C. Carrasco-Cubero, et al. "OP0212 ABATACEPT IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 263 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 132.1–132. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1748.
Full textAbstract:
Background:Interstitial Lung Disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Several conventional disease-modifying anti-rheumatic drugs (cDMARDs) and biologic (b) DMARDs may induce or impaired ILD-RA. Abatacept (ABA) may be useful in ILD-RA (1).Objectives:To assess the efficacy and safety of ABA in a large series of ILD-RA for a long-term follow-up.Methods:Multicenter open-level study of ILD-RA treated with at least 1 dose of ABA. ILD was diagnosed by high-resolution computed tomography (HRTC). We study these outcomes: a) 1-point change Modied Medical Research Council (MMRC); b) forced vital capacity (FVC) and/or DLCO improvement or decline ≥10%; c) change in HRCT, d) change in DAS28. e) Prednisone dose. Values were collected at 0, 3, 6, 12 and then every 12 months.Results:We studied 263 patients (150 women/113 men) (mean age;64.6±10 years), with ILD-RA. At ABA-onset they were smokers or exsmoker (53.8%), positive APCC (88.6%), median [IQR] duration of ILD of 12 [3-41.25] months, mean DLCO (65.7±18.3) and FVC (85.9±21.8).The ILD-pattern were usual interstitial pneumonia (UIP) (40.3%), non-specific interstitial pneumonia (NSIP) (31.9%) and others (27.8%).ABA was prescribed at standard subcutaneous (125 mg/w) in 196 (74.5%) or intravenously (10 mg/kg/4 w) in 67 (25.5%); in monotherapy (n=111) or combined with cDMARDs (n=152); especially leflunomide (n=55), MTX (n=46), or antimarials (n=21).After a mean follow-up of 22.7±19.7 months most outcomes remain stable (Figure). Moreover, DAS28 improved from 4.5±1.5 to 3.1±1.3; prednisone dose reduced from a median 7.5 [5-10] to 5 mg [5-7.5] and retention rate was 76.4%. The main adverse effects were serious infections (n=28), neoplasia (n=3), serious infusion reaction (n=1) and myocardial infarction (n=1).Conclusion:ABA seems effective and relatively safe in ILD-RA.References:[1]Fernández-Díaz C et al. Semin Arthritis Rheum. 2018; 48:22-27Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer.CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
12
Fernández-Díaz, C., S. Castañeda, R. Melero, J. Loricera, F. Ortiz-Sanjuán, A. Juan-Mas, C. Carrasco-Cubero, et al. "SAT0035 RESPONSE TO ABATACEPT OF DIFFERENT PATTERNS OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: NATIONAL MULTICENTER STUDY OF 263 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 947.1–948. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1741.
Full textAbstract:
Background:Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA). In this line, several radiological patterns of RA-ILD have been described: i) usual interstitial pneumonia (UIP), ii) nonspecific interstitial pneumonia (NSIP), iii) obliterating bronchiolitis, iv) organized pneumonia and mixed patterns. Abatacept (ABA) could be an effective and safe option for patients with RA-ILD, although the response in the different radiological patterns is not well defined.Objectives:Our aim was to assess the response to ABA in different radiological patterns of ILD.Methods:Observational retrospective multicenter study of RA-ILD treated with ABA. ILD was diagnosed by HRCT and classified by radiological patterns in 3 different subgroups of RA-ILD: a) UIP, b) NSIP and c) “other”. ABA was used sc. or iv. at standard dose. We assessed: a) Dyspnoea (MMRC scale; significant variation ≥1); b) Respiratory function tests (significant changes ≥10% in FVC and DLCO); c) HRCT imaging; d) DAS28 e)prednisone dose.Variables were collected at months 0, 3, 6, 12 months and subsequently every 12 months until a maximum of 60 months.Results:We included 263 patients: 106 UIP, 84 NSIP and 73 others (150 women / 113 men), mean age 64.64±10 years. Total patients positive for RF or CCPA were 235 (89.4%) and 233 (88.6%), respectively. In 26 out of 263 patients, the development of ILD was closely related to the administration of sDMARDs (MTX n = 11 and LFN n = 1) or bDMARDs (ETN n = 5, ADA n = 4, CZP n = 2 and IFX n = 3). Patient characteristics are shown in table 1. Figure 1 shows the evolution of the cases with available data after a mean follow-up of 22.7±19.7 months. Mean DLCO and FVC remained stable in the 3 groups without statistically significant changes, and all the groups showed a statistically significant reduction in DAS28 and prednisone dose.Conclusion:ABA could be a good choice of treatment in patients with RA-ILD independently of the radiological pattern of ILD.Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, R. López-Sánchez: None declared, Edilia García-Fernández: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
13
Fernández-Díaz, C., S. Castañeda, R. Melero, J. Loricera, F. Ortiz-Sanjuán, A. Juan-Mas, C. Carrasco-Cubero, et al. "SAT0075 ABATACEPT IN COMBINATION WITH METOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED TO INTERSTITIAL LUNG DISEASE: NATIONAL MULTICENTER STUDY OF 263 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 972.1–972. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1630.
Full textAbstract:
Background:Interstitial Lung Disease (ILD) is an extra-articular complication of rheumatoid arthritis (RA) that is associated with increased morbidity and mortality. Conventional disease-modifying drugs (DMARDs) such as methotrexate (MTX) have been implicated in the development and exacerbation of a pre-existing ILD.Objectives:The aim of our study was to check the influence of combined MTX treatment in patients with RA-ILD treated with abatacept (ABA).Methods:National multicentre retrospective registry of 263 patients with RA-ILD treated with ABA. RA was diagnosed according to the ACR classification criteria of 1987 or by the EULAR/ACR criteria of 2010. ILD was diagnosed by high resolution computed tomography (HRCT). In this study we have done a subanalysis of the 46 patients treated with ABA in combination with MTX (ABA+MTX) vs. 217 patients treated with ABA in monotherapy or in combination with other synthetic DMARDs. Efficacy was evaluated according to the following parameters: a) Dyspnoea (MMRC) considering variations ≥ 1; b) Lung function test (LFT) considering variations ≥ 10% in FVC and a variation of DLCO ≥ 10%; c) Imaging test (HRCT) d) DAS28 score e) prednisone dose. Variables were collected at the beginning of the study and at months 3, 6, 12 and then every 12 months until a maximum of 60 months.Results:263 patients with ILD associated with RA were included in the study with mean age 64.64±10 years. RF or CCPA were positive in 235 (89.4%) and 233 (88.6%) cases, respectively, with a mean follow-up of 22.7±19.7 months. Baseline characteristics of both groups are shown in table 1, while data obtained during evolution of this complication are presented in Figure 1.Conclusion:Despite the baseline differences of both groups, the good evolution in the ABA+MTX subgroup suggests that this therapeutic strategy can be a safe combination for patients with RA-ILD.ABA with MTX (n=46)ABA w/t MTX (n=217)PSex (F/M)28/18122/950.625Age (years)65.11±10.216.2±9.80.202RF/CCPA + (%)91.3/91.389.8/90.10.810Smoking or past smoking (%)47.855.10.417Follow-up (months)22.73±18.0022.3±20.850.916DAS28 at baseline4.08±1.514.61±1.470.056DAS28 at last visit3.00±1.463.13±1.310.642Prednisone at baseline, median (IQR) (mg)5 (5-7.5)7.75 (5-15)0.008*Prednisone at the end of study, median (IQR) (mg)5 (1-5)5 (5-7.5)0.032*DLCO at baseline (%)66.85±19.0465.43±18.210.823DLCO at the end of study (%)66.05±20.9565.17±19.720.831FVC at baseline (%)90.06±17.7785.40±21.560.164FVC at the end of study (%)90.58±15,4584.21±21.490.038*Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD
14
Jones, Meleri, Andrew Davidson, Linda Hibbert, Petra Gruenwald, Joerg Schlaak, Simon Ball, Graham R. Foster, and Michael Jacobs. "Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression." Journal of Virology 79, no. 9 (May 1, 2005): 5414–20. http://dx.doi.org/10.1128/jvi.79.9.5414-5420.2005.
Full textAbstract:
ABSTRACT Alpha/beta interferon (IFN-α/β) is a key mediator of innate antiviral responses but has little effect on the established replication of dengue viruses, which are mosquito-borne flaviviruses of immense global health importance. Understanding how the IFN system is inhibited in dengue virus-infected cells would provide critical insights into disease pathogenesis. In a recent study analyzing the ability of individual dengue virus-encoded proteins to antagonize the IFN response, nonstructural (NS) protein 4B and possibly NS2A and NS4A were identified as candidate IFN antagonists. In monkey cells, NS4B appeared to inhibit both the IFN-α/β and IFN-γ signal transduction pathways, which are distinct but overlapping (J. L. Munoz-Jordan, G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre, Proc. Natl. Acad. Sci. USA 100:14333-14338, 2003). For this study, we examined the effects of dengue virus on the human IFN system, using cell lines that were stably transfected with self-replicating subgenomic dengue virus RNA (replicons) and that expressed all of the dengue virus nonstructural proteins together. We show here that in replicon-containing cells dengue virus RNA replication and the replication of encephalomyocarditis virus, an IFN-sensitive virus, are resistant to the antiviral effects of IFN-α. The presence of dengue virus replicons reduces global IFN-α-stimulated gene expression and specifically inhibits IFN-α but not IFN-γ signal transduction. In cells containing replicons or infected with dengue virus, we found reduced levels of signal transducer and activator of transcription 2 (STAT2), which is a key component of IFN-α but not IFN-γ signaling. Collectively, these data show that dengue virus is capable of subverting the human IFN response by down-regulating STAT2 expression.
15
Nelson, Joe. "Reviewer Acknowledgements." World Journal of English Language 11, no. 2 (September 27, 2021): 185. http://dx.doi.org/10.5430/wjel.v11n2p185.
Full textAbstract:
World Journal of English Language wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal are greatly appreciated.World Journal of English Language is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please contact us for the application form at: wjel@sciedupress.comReviewers for Volume 11, Number 2Andrés Canga, University of La Rioja, SpainChunlin Yao, Tianjin Chengjian University, ChinaDaniel Ginting, Universitas Ma Chung, IndonesiaDon Anton Balida, Oman Tourism College, OmanElena Alcalde Peñalver, University of Alcalá, SpainEmine Bala, Tishk International University, IraqGhadah Al Murshidi, The United Arab Emirates University, UAEHameed Yahya Ahmed Al-Zubeiry, Al-Baha University, Saudi ArabiaHossein Salarian, University of Tehran, IranHouaria Chaal, Hassiba Ben Bouali University of Chlef, AlgeriaJasna Potocnik Topler, University of Maribor, SloveniaKanthimathi Krishnasamy, Shrimathi Devkunvar Nanalal Bhatt Vaishnav College for Women, IndiaKenan Yerli, Sakarya University, TurkeyLeila Lomashvili, Shawnee State University, USALi Ping Chang, Department of Applied Foreign Languages, National Taipei College of Business, TaiwanMaria del Mar Sanchez Ramos, University of Alcalá, SpainMaria Isabel Maldonado Garcia, Al-Andalus Institute of Languages University of Lahore, PakistanMaría Luisa Carrió, Universidad Politécnica de Valencia, SpainMuhammed Ibrahim Hamood, University of Mosul, IraqMustafa Ar, Ar-Raniry State Islamic University, IndonesiaNitin Malhotra, St. Theresa International College, Bangkok, ThailandÖzkanal, Ümit, Eskisehir Osmangazi University Foreign Languages Department, TurkeyPatnarin Supakorn, Walailak University, ThailandPham Vu Phi Ho, Van Lang University, VietnamScott-Monkhouse Anila Ruth, Language Centre – University of Parma (Italy), ItalyŞenel, Müfit, 19 Mayıs University, TurkeyShalini Yadav, Compucom Institute of Technology and Management, IndiaTeguh Budiharso, State Institute of Islamic Studies (IAIN) of Surakarta, Indonesia, IndonesiaWafi Fhaid Alshammari, University of Ha’il, Saudi ArabiaWenjie Shi, Central University of Finance and Economics, China
16
Siraisi, Nancy G. "Arnaldi de Villanova opera medica omnia. Volume XV: Commentum supra tractatum Galieni De malicia complexionis diverse. Arnald of Villanova , Luis Garcia Ballester , Eustaquio Sanchez SalorDoctrina Galieni De Interioribus. Richard J. Durling." Isis 77, no. 2 (June 1986): 367–68. http://dx.doi.org/10.1086/354179.
Full text
17
Marzal, Vicente, Juan Carlos Torres, Braulio García, Isabel Pérez, José Manuel Sánchez, and Wiktor Piecek. "Study of electrical behavior of liquid crystal devices doped with titanium dioxide nanoparticles." Photonics Letters of Poland 9, no. 1 (March 31, 2017): 20. http://dx.doi.org/10.4302/plp.v9i1.712.
Full textAbstract:
In the last years, nanostructures are widely used as dopants in liquid crystals to manipulate either their electrical or optical properties. In this work, we have analyzed the electrical response of a planar cell filled with a mixture of E7 liquid crystal doped with TiO2 nanoparticles. The effect of these dopants on the effective permittivity and conductivity of the cell has been studied in a wide frequency range at different temperatures. Full Text: PDF ReferencesP.J. Pinzón, I. Pérez, C. Vázquez and J.M.S. Pena, "Reconfigurable ????×????1×2 wavelength selective switch using high birefringence nematic liquid crystals", App.Opt. 51, pp.5960-5965 (2012) CrossRef C. Carrasco-Vela, X. Quintana, E.Otón, M.A. Geday, J.M. Otón, "Security devices based on liquid crystals doped with a colour dye", Opto?Electron. 19, pp.496-500 (2011). CrossRef J. Torrecilla, E. Ávila-Navarro, C. Marcos, V. Urruchi, J.M.S. Pena, J. Arias, M.M Sánchez-López, "Microwave Tunable Notch Filter Based on Liquid Crystal Using Spiral Spurline Technology", Microw. Opt. Technol. Lett. 55, 2420-2423 (2013). CrossRef G.B. Hadjichristov, Y. G. Marinov, A. G. Petrov, E. Bruno, L.Marino, N. Scaramuzzab, "Electro-Optics of Nematic/Gold Nanoparticles Composites: The Effect from Dopants", Mol. Cryst. Liq. Cryst. 610, 135?148 (2015). CrossRef T. Miyama, J. Thisayukta, H. Shiraki, Y. Sakai, Y. Shiraishi, N. Toshima, S. Kobayashi, "Fast Switching of Frequency Modulation Twisted Nematic Liquid Crystal Display Fabricated by Doping Nanoparticles and Its Mechanism", Jpn. J. Appl. Phys. 43, 2580 -2584 (2004). CrossRef W. T. Chen, P. S. Chen, C. Y. Chao, "Effect of Doped Insulating Nanoparticles on the Electro-Optical Characteristics of Nematic Liquid Crystals", Jpn. J. Appl. Phys. 48, 015006 (2009) CrossRef A. Siarkowska, M. Chychłowski, T.R. Woliński and A.Dybko. "Titanium nanoparticles doping of 5CB infiltrated microstructured optical fibers", Phot. Lett. Poland 8, 29-31 (2016). CrossRef O. Buchnev, A. Dyadyusha,M. Kaczmarek, V.Reshetnyak, Y. Reznikov, "Enhanced two-beam coupling in colloids of ferroelectric nanoparticles in liquid crystals", J. Opt. Soc. Am. 24, 1512-1516 (2004). CrossRef A. García-García, R. Vergaz, J.A. Algorri, X. Quintana, J.M. Otón, Beilstein J. "Electrical response of liquid crystal cells doped with multi-walled carbon nanotubes", Nanotechnol. 6, 396?403 (2015). CrossRef R. Pratibha, K. Park, I.I. Smalyukh and W. Park, "Tunable optical metamaterial based on liquid crystal-gold nanosphere composite", Opt. Express 17,19459-19469 (2009). CrossRef J.C. Torres, B. Garcia-Camara, I. Perez, V. Urruchi, J.M. Sanchez-Pena, "Temperature-Phase Converter Based on a LC Cell as a Variable Capacitance", Sensors 15, 5594 ? 5608 (2015). CrossRef P. Kumar, A. Kishore and A, Sinha, "Effect of different concentrations of dopant titanium dioxide nanoparticles on electro-optic and dielectric properties of ferroelectric liquid crystal mixture ", Adv. Mater. Lett. 7, 104-110 (2016). CrossRef R.K. Shukla, C.M. Liebig, D.R. Evans, and W. Haase, "Electro-optical behaviour and dielectric dynamics of harvested ferroelectric LiNbO3 nanoparticle-doped ferroelectric liquid crystal nanocolloids", RSC Adv. 4, 18529-18536 (2014). CrossRef
18
SANCHEZ-GARCIA, M., C. ROYO, N. APARICIO, J. A. MARTÍN-SÁNCHEZ, and F. ÁLVARO. "Genetic improvement of bread wheat yield and associated traits in Spain during the 20th century." Journal of Agricultural Science 151, no. 1 (April 17, 2012): 105–18. http://dx.doi.org/10.1017/s0021859612000330.
Full textAbstract:
SUMMARYA collection of 26 wheat genotypes widely grown in Spain during the 20th century was evaluated in eight contrasting environments in order to quantify breeding achievements in yield and associated traits. From 1930 to 2000, yield increased at a rate of 35·1 kg/ha/yr or 0·88%/yr, but estimations of relative genetic gain (RGG) were environment-dependent. RGG estimated for yield were positively associated with the average minimum daily temperatures from sowing to heading in the testing environments (R2 = 0·81; P < 0·01). The number of grains/spike and the number of spikes/m2 increased at a rate of 0·60%/yr and 0·30%/yr, respectively, while grain weight remained unchanged. The present study detected two main episodes of yield improvement during the century. The first one coincided with the introduction, during the 1950s, of the first improved cultivars derived from intra-specific crosses, which increased the yield of landraces by 30% due to an increase of c. 58% in the number of grains/spike, accompanied by a 16% reduction in grain weight. These initial cultivars (termed ‘old-bred’ in a previous study by Sanchez-Garcia et al. 2012) exhibited a higher harvest index (HI), increased from 0·25 to 0·40, but maintained the same aboveground biomass at maturity as the landraces (despite reducing both plant height and the number of tillers/plant) due to increases in the proportion of tillers bearing spikes. The second yield gain occurred after the introduction, in the early 1970s, of semi-dwarf germplasm from CIMMYT (International Maize and Wheat Improvement Centre) and some French cultivars. This new germplasm further reduced plant height, improved HI up to 0·45 and increased the number of tillers/plant while maintaining their rate of fertility, thus resulting in a yield gain of c. 37%. The cultivars released during the last decade of the century did not contribute to significant yield improvements.
19
Sánchez, Álvaro I., Mónica Morales, and Juan S. Calle Toro. "Trauma en ancianos – Experiencia de dos hospitales de referencia en Cali, Colombia." Panamerican Journal of Trauma, Critical Care & Emergency Surgery 5, no. 1 (2016): 38–42. http://dx.doi.org/10.5005/jp-journals-10030-1141.
Full textAbstract:
RESUMEN Introducción El trauma es una causa común de consulta a servicio de emergencia en Cali, Colombia. De todas las consultas a urgencias el 30% representan trauma, siendo la 5 causa de mortalidad. Las características demográficas y el patrón del trauma que reciben los ancianos no han sido profundamente estudiados en países de ingresos medios. El objetivo de nuestro trabajo es caracterizar las lesiones relacionadas con trauma en pacientes ancianos e identificar posibles medidas preventivas. Métodos Un análisis secundario de la base de datos del registro de la Sociedad Panamericana de Trauma implementado en dos centros de referencia para trauma en Cali, Colombia, durante el periodo 2012-2013. Se incluyeron pacientes de 65 años o mayores. Las variables que se analizaron fueron demográficas, características de las lesiones, score de severidad del trauma (ISS), información clínica al ingreso, e información relacionada con la disposición final del paciente. Resultados De 14315 pacientes registrados en la base de datos de trauma, 1372 (10%) eran mayores de 65 años. La edad media de este grupo fue 74 años (DE ± 9.7). Los hombres fueron 723 (53%) de pacientes estudiados. El mecanismo primario de lesión traumática fueron las caídas en 984 (72%) seguido de las relacionadas a eventos de transito en 195 (14%). El 95% de los pacientes tuvieron un ISS<16. Un total de 285 (20%) requirieron como mínimo una cirugía y 261 (19%) fueron transferidos a otro hospital para continuar el manejo medico. La mortalidad de este grupo fue de 81 (6%) pacientes vs 715 (5%) de la mortalidad global. La mediana de estancia hospitalaria fue de 1 día (rango intercuartilico de 1-4). Discusión Los pacientes ancianos representan una proporción importante de los traumatizados atendidos en urgencias. La causa más común de estas lesiones son las caídas y los relacionados con eventos de transito. La mayor proporción de los pacientes tuvieron un ISS bajo. Sin embargo, la mortalidad de este grupo etáreo superó a la mortalidad global. Muchos de los pacientes ancianos requirieron cirugía, llevando esto a mayor morbi/mortalidad y gastos económicos elevados. La prevención primaria es necesaria para disminuir el impacto en salud y económico que genera para el sistema de salud. How to cite this article Calle Toro JS, Sanchez AI, Morales M, Garcia AF. Trauma en ancianos – Experiencia de dos hospitales de referencia en Cali, Colombia. Panam J Trauma Crit Care Emerg Surg 2016;5(1):38-42.
20
Martin-Martinez, M. A., S. Castañeda, F. Sánchez-Alonso, C. García Gomez, C. Gonzalez Juanatey, M. A. Belmonte, J. Tornero, et al. "OP0002 INCIDENCE OF FIRST CARDIOVASCULAR EVENT IN SPANISH PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: PROSPECTIVE DATA FROM THE CARMA PROJECT AFTER 5 YEARS OF FOLLOW-UP." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 2.2–2. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4711.
Full textAbstract:
Objectives:To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) attending Spanish rheumatology clinics after 5 years of follow-upMethods:Analysis of data of patients included in an observational prospective study [CARdiovascular in rheuMAtology (CARMA) project] after 5 years of follow-up. The study includes a cohort of 2234 patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), and another cohort of matched individuals (n=677) without CIRD from 67 hospitals in Spain. Cumulative incidence per 1000 patients of CVE was estimated in both cohorts at 5 years from the start. Weibull proportional hazard model was used to calculate the Hazard Ratio (HR) and 95% confidence intervals (CI) of the risk factors involved in the development of CV events. Losses to follow-up and their causes were also analyzed.Results:The total number patient who completed the follow-up visit at 5 years was 2.382 (81.9%). Fifteen patients died due to CVE and sixty due to non-CVE. The patients with CIRD showed higher cardiovascular cumulative incidence (40.5; 95% CI: 36.2-44.8) than controls (28.3; 95% CI: 21.8-34.8). The higher risk of developing a first CVE during the 5 years of follow-up was seen in patients with AS (HR: 4.60; 95% CI: 1.32-15.99; p=0.02), those with older age (HR:1.09; 95% CI: 1.05-1.13; p<0.001), higher systolic blood pressure (HR: 2.64; 95% CI: 1.32-5.25; p=0.006), and those with longer duration of the rheumatic disease (HR: 1.07; 95% CI: 1.03-1.12; p=0.002). In contrast, woman gender was a protective factor (HR: 0.45; 95% CI: 0.21-0.99; p=0.047).Conclusion:Patients with AS prospectively followed-up at rheumatology outpatient clinics showed higher risk of developing a first CVE than those without CIRD. Besides traditional CV disease risk factors, a longer time course of the disease is a risk factor for the development of CV disease in patients with CIRD.Acknowledgments:This project has been supported by an unrestricted grant from Abbvie, Spain. The design, analysis, interpretation of results and preparation of the manuscript has been done independently of Abbvie.Disclosure of Interests:Maria Auxiliadora Martin-Martinez: None declared, Santos Castañeda: None declared, Fernando Sánchez-Alonso: None declared, Carmen García Gomez: None declared, Carlos Gonzalez Juanatey: None declared, Maria Angeles Belmonte: None declared, Jesús Tornero: None declared, José Santos Rey: None declared, CARMEN OLGA SANCHEZ GONZALEZ: None declared, Estefanía Quesada-Masachs: None declared, MARIA DELPUERTO MORENO GIL: None declared, Tatiana Cobo-Ibáñez: None declared, Jose Antonio Pinto Tasende: None declared, Jesús Babío: None declared, Gemma Bonilla: None declared, Antonio Juan Mas: None declared, Javier Manero: None declared, Montserrat Romera: None declared, Javier Bachiller-Corral: None declared, Eugenio Chamizo Carmona: None declared, Javier Calvo: None declared, Raimon Sanmarti: None declared, Maria Celia Erausquin: None declared, Rosario Garcia de Vicuna Grant/research support from: BMS, Lilly, MSD, Novartis, Roche, Consultant of: Abbvie, Biogen, BMS, Celltrion, Gebro, Lilly, Mylan, Pfizer, Sandoz, Sanofi, Paid instructor for: Lilly, Speakers bureau: BMS, Lilly, Pfizer, Sandoz, Sanofi, Carmen Barbadillo: None declared, Sergio Ros Exposito: None declared, Javier del Pino Grant/research support from: Roche, Bristol, Consultant of: Gedeon, MARIA JOSE GONZALEZ: None declared, José Manuel Pina Salvador: None declared, Javier Llorca: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD
21
García-Morales, Leccinum J., Jesús García-Jiménez, and Duilio Iamonico. "Agave lexii (Asparagaceae: Agavoideae), a New Species from Mexico." Novon, A Journal for Botanical Nomenclature 27, no. 4 (October 3, 2019): 201–4. http://dx.doi.org/10.3417/2019402.
Full textAbstract:
A new species of Agave L. (Asparagaceae: Agavoideae), A. lexii García-Morales, García-Jiménez & Iamonico, from Tamaulipas (northeastern Mexico) is described and illustrated. The new species is morphologically similar to A. tenuifolia Zamudio & E. Sanchez and A. striata Zucc. Agave lexii differs from A. tenuifolia and A. striata in leaf arrangement, size, and color, flower number and length, and fruit size. The distribution of A. lexii in Mexico, notes on its preferential habitat and phenology, and an assessment of its IUCN conservation status are provided.
22
Prieto Lasa, J. Ramón. "Zorrilla y la poética del éxito: Sancho García." Revista de literatura 74, no. 148 (December 30, 2012): 447–72. http://dx.doi.org/10.3989/revliteratura.2012.02.312.
Full text
23
Massanell i Messalles, Mar. "Josep Vicent Garcia Sebastià, «Les construccions de temps transcorregut en el català de l’edat moderna i contemporània (s. XVI-XX)», València/Barcelona, Institut Interuniversitari de Filologia Valenciana / Publicacions de l’Abadia de Montserrat, 2019, col. «Biblioteca Sanchis Guarner», 90, 202 p." Caplletra. Revista Internacional de Filologia, no. 70 (April 22, 2021): 285. http://dx.doi.org/10.7203/caplletra.70.20009.
Full textAbstract:
Ressenya sobre el llibre de Josep Vicent Garcia Sebastià, Les construccions de temps transcorregut en el català de l’edat moderna i contemporània (s. XVI-XX), València/Barcelona, Institut Interuniversitari de Filologia Valenciana / Publicacions de l’Abadia de Montserrat, 2019, col. «Biblioteca Sanchis Guarner», 90, 202 p., ISBN: 978-84-9191-155-9.
24
Chastre, Jean, Bruno François, Marc Bourgeois, Apostolos Komnos, Ricard Ferrer, Galia Rahav, Nicolas De Schryver, et al. "635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S377—S378. http://dx.doi.org/10.1093/ofid/ofaa439.829.
Full textAbstract:
Abstract Background Pseudomonas aeruginosa (PA) pneumonia is associated with morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, and safety of MEDI3902 in MV ICU subjects in the placebo-controlled, randomized Phase 2 EVADE study (NCT02696902; EudraCT 2015-001706-34). Methods Subjects with PCR-confirmed PA colonization of the lower respiratory tract were randomized to either a single IV infusion of 1,500 mg MEDI3902 (n = 85) or placebo (n = 83). Primary Efficacy endpoint was Endpoint Adjudication Committee-determined relative risk reduction (RRR) of PA pneumonia incidence in MEDI3902 vs. placebo recipients within 21 days post dose (2-sided α = 0.2). Serum MEDI3902 PK levels were measured through 49 days post dose. Treatment-emergent adverse events (TEAEs) and serious AEs (SAEs) were assessed through 49 days post dose. Results Baseline characteristics were similar between groups. MEDI3902 did not meet the primary endpoint of PA pneumonia vs. placebo (22.4% vs. 18.1%; RRR -23.7%, P = 0.491). Mean serum MEDI3902 level was 9.46 µg/mL (target 1.7µg/mL) at 21 days post dose, with a t½ 5.6 days. Proportion of subjects with TEAEs was similar between groups: ≥1 TEAE (98.8% MEDI3902; 97.6% placebo); ≥1 serious; and/or ≥grade 3 severity SAE (70.6% MEDI3902; 66.3% placebo). Deaths were numerically higher, although not statistically significant (24 (28.2%) MEDI3902 vs 19 (22.9%) Placebo; RRR -23.3%, P 0.429). Post-hoc analyses suggested RRR 47% among ~70% of the study population who had baseline Procalcitonin levels < 0.55 µg/L (12.5% MEDI3902 vs 23.7% placebo; 80%CI 6.1%-69.9%; P 0.135). Similarly, RRR 83% was observed among 50% of study subjects with baseline absolute neutrophil count (ANC) of < 8170 /µL (2.8% MEDI3902 vs 17.0% placebo; 80%CI 39.5%-95.5%; P 0.038). Subjects with Procalcitonin < 0.55 µg/L and ANC < 8170/ µL also had higher serum PK exposure. Conclusion A single IV dose of MEDI3902 provided PK exposure above the target level but did not achieve primary efficacy endpoint of reduction in PA pneumonia. Efficacy trends were observed in subjects with lower levels of baseline inflammatory biomarkers. MEDI3902 may have a path forward in certain patient populations such as ICU patients with lower baseline inflammation. Disclosures Jean Chastre, MD, AstraZeneca (Scientific Research Study Investigator) Marc Bourgeois, MD, AstraZeneca (Scientific Research Study Investigator) Apostolos Komnos, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Ricard Ferrer, MD, PhD, Shionogi B.V. (Advisor or Review Panel member) Galia Rahav, MD, AstraZeneca (Scientific Research Study Investigator) Nicolas De Schryver, MD, AstraZeneca (Scientific Research Study Investigator) Alain Lepape, MD, AstraZeneca (Scientific Research Study Investigator) Miguel Sanchez Garcia, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Antoni Torres, MD, PhD, AstraZeneca (Scientific Research Study Investigator) Omar Ali, PhD, AstraZeneca (Employee) Kathryn Shoemaker, MS, AstraZeneca (Employee) Alexey Ruzin, PhD, AstraZeneca (Employee, Shareholder) Yu Jiang, PhD, AstraZeneca (Employee) Susan Colbert, BSN, AstraZeneca (Employee) Drieke Vandamme, PhD, AstraZeneca (Scientific Research Study Investigator) Terramika Bellamy, n/a, AstraZeneca (Employee) Colin Reisner, MD, AstraZeneca (Employee) Filip Dubovsky, MD, MPH, AstraZeneca (Employee) Hasan S. Jafri, MD, FAAP, AstraZeneca (Employee)
25
Horcajada, M. N., M. Beaumont, N. Sauvageot, L. Poquet, M. Saboudjian, A. C. Hick, B. Costes, L. Garcia, and Y. Henrotin. "FRI0653-HPR AN OLEUROPEIN-BASED DIETARY SUPPLEMENT IMPROVES JOINT FUNCTIONALITY IN OLDER PEOPLE WITH HIGH KNEE JOINT PAIN." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 930.2–930. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3655.
Full textAbstract:
Background:OLE provides oleuropein the most prevalent phenolic component in olive leaves and has been shown to have potent anti-inflammatory and anti-oxidant effects potentially interesting for joint health (1).Objectives:The aim of this study was to investigate the effects of a 6-month intervention with an Olive Leaf Extract (OLE) standardized for oleuropein content on knee functionality and biomarkers of bone/cartilage metabolism and inflammation.Methods:The study was a randomized, double-blind, placebo-controlled, multi-centric trial of 124 subjects with mild knee pain or mobility issues. Subjects were randomized equally to receive twice a day one capsule of either maltodextrin (control treatment, CT) or 125-mg OLE (BonoliveTM, an Olive Leaf Extract containing 50 mg of Oleuropein) for 6 months. The co-primary endpoints were Knee injury and Osteoarthritis Outcome Score (KOOS) using a self-administered questionnaire and serum Coll2-1NO2 specific biomarker of cartilage degradation. The secondary endpoints were each of the five sub-scales of the KOOS questionnaire, Knee pain VAS score at rest and at walking, OARSI core set of performance-based tests and serum biomarkers (Coll2-1, MPO, CTX1, osteocalcin, PGE2 and Vplex cytokines assay in serum) and concentration of Oleuropein’s metabolites in urine.Results:Primary (global KOOS score, biomarker Coll2-1 NO2) and secondary endpoints (the five subscales of the KOOS score) improved time dependently in both groups. OLE treatment showed significantly elevated urinary oleuropein metabolites (oleuropein aglycone, hydroxytyrosol, homovanillyl alcohol and isomer of homovanillyl alcohol), and was well tolerated without significant differences in number of subjects with adverse events. At 6 months, OLE group showed a higher global KOOS score compared to placebo (treatment difference = 3.73; 95% CI = [-4.08;11.54]; p = 0.34), without significant changes of inflammatory and cartilage remodeling biomarkers. Subgroup analyses demonstrated a large and significant treatment effect of OLE in subjects with high walking pain at baseline (14.4; 95% CI = [1.19;27.63], p=0.03). This was observed at 6 months for the global KOOS score and each different subscale and for pain at walking (-23.07;95% CI = [-41.8;-4.2];p=0.02). These treatment effects at 6 months were significant for KOOS score as well as for the subscales Pain and QoL and the pain at walking.Conclusion:OLE was not effective on joint discomfort in people with low to moderate pain at baseline but significantly benefited subjects with high pain at treatment initiation. As oleuropein is well-tolerated, OLE can be used to relieve knee joint pain and enhance mobility in subjects with articular pain the most painful subjects.References:[1] Horcajada MN, Sanchez C, Membrez Scalfo F, Drion P, Comblain F, Taralla S, Donneau AF, Offord EA, Henrotin Y. Oleuropein or rutin consumption decreases the spontaneous development of osteoarthritis in the Hartley guinea pig. Osteoarthritis Cartilage. 2015 Jan;23(1):94-102Disclosure of Interests:Marie-Noelle Horcajada Employee of: nestlé, Maurice Beaumont Employee of: nestle, Nicolas Sauvageot Employee of: Nestlé, Laure Poquet Employee of: Nestlé, Madleen Saboudjian Employee of: Nestlé, Anne-Christine Hick Employee of: Artialis SA, Berenice Costes Employee of: Artialis SA, Laetitia Garcia Employee of: Artialis, Yves Henrotin Grant/research support from: HEEL, TILMAN
26
Virmond, Marcos da Cunha Lopes, and Lenita Waldige Mendes Nogueira. "Veni Sancte Spiritus: um moteto de José Maurício Nunes Garcia." Per Musi, no. 24 (December 2011): 167–71. http://dx.doi.org/10.1590/s1517-75992011000200017.
Full textAbstract:
A produção musical no gênero sacro teve importantes representantes no período do Brasil Colônia e Imperial, entre os quais se destaca o Padre José Maurício Nunes Garcia, responsável pela música da Sé Imperial do Rio de Janeiro antes e após a chegada da família real em 1808. Sua vasta produção resistiu ao tempo através de manuscritos autógrafos ou não, os quais têm sido alvo de intensos estudos, com destaque para as pesquisas pioneiras de Cleofe Person de Mattos. Mesmo assim, atualmente, apenas parte de sua obra encontrase restaurada do ponto de vista musicológico com vistas à perfomance. Desta forma, este estudo visa comentar a transcrição musicológica de um moteto de exemplar fatura, intitulado Veni Sancte Spiritus, para pequena orquestra de cordas, duas flautas e coro a quatro vozes.
27
Audo, R., P. Sanchez, J. Mielle, L. Macia, B. Rivière, C. Lukas, B. Combe, J. Morel, and C. Daien. "OP0035 ASSESSMENT OF THE INTESTINAL PERMEABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING COLONIC TISSUES AND SERA." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 19.2–19. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2642.
Full textAbstract:
Background:Patients with rheumatoid arthritis (RA) have an altered gut microbiota (dysbiosis) (1-3). This microbiota interacts with intestinal epithelium which can lead to an increased intestinal permeability, responsible for the passage of antigens and inflammatory molecules, and can therefore promote systemic inflammation. Gut microbiota tends to normalize with disease control (2), suggesting that systemic inflammation may directly influence the composition of microbiota and the gut barrier. It was shown in many inflammatory diseases that intestinal permeability is impaired, but to date there is very little data in RA.Objectives:In the present study, we evaluate the intestinal permeability in RA patients by analyzing tight junctions in colonic biopsies and serum markers.Methods:Colonic biopsies from 20 RA patients who underwent coloscopy for screening with normal histology were compared with those from 20 age and sex matched controls. ZO-1, occludin and claudin 2 junction proteins were evaluated by immunohistochemistry. The staining intensity was assessed by two blinded independent readers. The serum concentrations of LPS-binding protein (LBP), CD14s and zonulin were evaluated by ELISA in 25 patients naive of DMARDs, 41 patients before and after introduction of a DMARDs and 21 controls. Elevated zonulin in serum indicates an increase in intestinal permeability while LBP and CD14s indicate bacterial translocation.Results:ZO-1 expression was significantly lower in biopsies from patients with RA than controls (mean score ± SD of 1.6 ± 0.56 vs 2.0 ± 0.43; p = 0.01). Age, sex, disease duration and immunological status did not significantly influence the expression of colonic junction proteins. LBP and CD14s were higher in serum from RA patients naive of DMARDs than controls (p = 0.002 and p = 0.003). LBP, CD14s and zonulin levels significantly correlated with DAS28 (r = 0.61, p = 0.005; r = 0.51, p = 0.030 and r = 0.46, p = 0.049, respectively). After treatment, unlike non-responders, LBP and CD14s were significantly reduced in DMARD responders and variations in LBP and CD14s significantly correlated with changes in DAS28 (r = 0.46, p = 0.002 and r = 0, 33 and p = 0.030, respectively).Conclusion:This work is one of the first to explore intestinal permeability in RA and to show altered tight junction in colonic tissue from RA. This increased intestinal permeability appears to be related to the systemic inflammation. Improving the gut microbiota through food or probiotics could enhance the effect of treatments by limiting this amplification loop of inflammation.References:[1]Horta-Baas G, Romero-Figueroa MDS, Montiel-Jarquin AJ, Pizano-Zarate ML, Garcia-Mena J, Ramirez-Duran N. Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis. J Immunol Res. 2017;2017:4835189.[2]Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895-905.[3]Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, et al. Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis Rheumatol. 2016;68(11):2646-61.Disclosure of Interests:Rachel Audo: None declared, Pauline Sanchez: None declared, Julie Mielle: None declared, Laurence Macia: None declared, Benjamin Rivière: None declared, Cédric Lukas: None declared, Bernard Combe: None declared, Jacques Morel: None declared, Claire Daien Speakers bureau: Pfizer roche chugai fresenius BMS msd Novartis galapagos, Consultant of: Abivax abbbvie BMS roche chugai, Grant/research support from: Pfizer, roche-chugai, fresenius, msd
28
Albiac Blanco, María-Dolores. "Cetros y Puñales. [Don Sancho Garcia y la filosofía del poder]." Bulletin Hispanique 96, no. 2 (1994): 335–52. http://dx.doi.org/10.3406/hispa.1994.4837.
Full text
29
Piya, Sujan, Seemana Bhattacharya, Hong Mu, Vivian Ruvolo, Natalia Baran, Teresa McQueen, R. Eric Davis, et al. "Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL." Blood 132, Supplement 1 (November 29, 2018): 890. http://dx.doi.org/10.1182/blood-2018-99-115692.
Full textAbstract:
Abstract Background: Persistence of leukemia initiating cells (LIC) in T acute lymphoblastic leukemia (T-ALL) results in relapse in 20- 25% of pediatric and over 50% of adult patients1. LIC are characterized by high CD44 expression and low reactive oxygen species (ROS) levels 2, 3. T-ALL LIC maintain low ROS by cystine/glutamate anti-porter complex of which CD44 is a key component 2, 4. CD44 also interacts with microenvironmental components; hyaluronic acid, osteopontin, fibronectin etc. NOTCH1 transcriptionally upregulates CD44/MYC by binding the upstream 'super-enhancer' sites. BRD4, a member of the bromodomain and extra terminal domain (BET) family, is a critical scaffold of super-enhancer complexes that binds acetylated histones (3 and 4) and drives NOTCH1 mediated MYC/CD44 transcription 5, 4, 1. We hypothesized that degradation of BRD4 with hetero-bifunctional PROteolysis TArgeting Chimera (PROTACTM) such as ARV-825, will lead to efficient and sustained downregulation of NOTCH1/MYC /CD44 transcription and disrupt cell intrinsic and extrinsic pathways for persistence of T-ALL LIC. Methods: We confirmed the anti-leukemia effect of ARV-825 (IC50 pico to low nanomolar) against T-ALL cells including early T-cell phenotype (ETP) and Gamma-secretase inhibitor (GSI) resistant T-ALL8. To confirm disruption of NOTCH1/MYC/CD44 axis in-vivo, we specifically tested the impact of BRD4 degradation on NOTCH1 and its target genes including MYC, CD44 and as functional readout, intra-cellular ROS, in a T-ALL/ patient-derived xenograft (PDX) mouse model of disseminated leukemia possessing a constitutively active NOTCH1 mutation. Mass cytometry based proteomic analysis (CyTOF) studies were done to quantitatively assess T-ALL LICs and suppression of NOTCH1-MYC-CD44 axis, and secondary transplantation was carried out into sub-lethally irradiated mouse recipients to functionally evaluate LIC elimination. Results: ARV-825 mediated sustained BRD4 degradation resulted in profound down-regulation of MYC, CD98, CD44 and its variants (CD44v). Moreover, we observed down-regulation of cell intrinsic anti-apoptotic proteins Bcl-2, Bcl-XL. As a functional correlate of down-regulation of CD98/CD44/CD44v (glutathione anti-porter system), flow cytometry confirmed increased intracellular ROS and decreased reduced glutathione (GSH). In a PDX mouse model of human T-ALL, ARV-825 treatment improved survival compared to mice treated with vehicle (P=0.002) (Fig.1). CyTOF analysis of mouse bone marrow cells showed quantitative reduction of phenotypically defined LIC (CD4+CD8+CD7+ CD19- ) 6,7 with down regulation of the NOTCH1-MYC-CD44 axis along with oncogenic molecules (transcription factors Myc and NFkB, cell cycle regulators, activated PI3K/Akt, and anti-apoptotic Bcl2 family proteins) in mice treated with ARV-825 (Fig.2). Finally, secondary transplantation of equal number of human CD45+ cells from Vehicle and ARV-825 treated mice in to NSG mice led to delayed leukemia development and extended survival of mice engrafted from ARV-825 treated mice (Vehicle:38 days Vs ARV-825: 58 days P=0.0001/ Vehicle:36.5 days Vs ARV-825: 50 days P=0.0001) (Fig.3), providing functional confirmation of LIC elimination. Conclusion: Degradation of BRD4 with PROTAC (ARV-825), modulates the NOTCH1/MYC/CD44 axis and has the potential of therapeutically targeting the LIC in T-ALL. Reference Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Journal of clinical oncology 2011; 29(5): 551-565. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al.Cancer cell 2011; 19(3): 387-400. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al.Nature 2009; 458(7239): 780-783. Garcia-Peydro M, Fuentes P, Mosquera M, Garcia-Leon MJ, Alcain J, Rodriguez A et al.The Journal of clinical investigation 2018. doi: 10.1172/JCI92981 Sanchez-Martin M, Ferrando A. Blood 2017; 129(9): 1124-1133. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Blood 2007; 109(2): 674-682. Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S et al.Leukemia 2011; 25(8): 1249-1258. Sujan Piya, Hong Mu, Seemana Bhattacharya, Teresa McQueen, R. Eric Davis, Vivian Ruvolo, Natalia Baran, Yimin Qian, Craig M. Crews, M. James You , Patrick Zweider-McKay, Marina Konopleva, Hagop Kantarjian , Michael Andreeff1, Gautam Borthakur. 59 th Annual Meeting &Exposition, Atlanta GA: December 9-12, 2017. Disclosures Qian: Arvinas LLC Inc: Employment. Raina:Arvinas LLC Inc: Employment. Konopleva:Stemline Therapeutics: Research Funding. Andreeff:Aptose: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Oncoceutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Reata: Equity Ownership; SentiBio: Equity Ownership; Oncolyze: Equity Ownership; Eutropics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Research Funding; Daiichi-Sankyo: Consultancy, Patents & Royalties: MDM2 inhibitor activity patent, Research Funding; United Therapeutics: Patents & Royalties: GD2 inhibition in breast cancer ; Jazz Pharma: Consultancy; Celgene: Consultancy; Amgen: Consultancy, Research Funding.
30
Valero, M., J. Bachiller-Corral, B. A. Blanco Cáceres, M. Á. Blázquez, C. Díaz-Miguel, M. J. Garcia Villanueva, C. Larena, et al. "FRI0301 DO PATIENTS AND PHYSICIANS AGREE ON THE DEFINITION OF REMISSION AND LOW DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS?" Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 740.1–740. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3301.
Full textAbstract:
Background:Current recommendations for axial Spondyloarthritis (axSpA) include the treat-to-target concept and suggest that the ideal target should be remission or low disease activity (LDA). Also, the importance of a shared decision is highlighted. Unfortunately, the definition of remission is not consensual, and most of the definitions are difficult to evaluate in clinical practiceObjectives:To propose an evaluation of remission by a single question to the patient, by comparing it to the different available definitions. To analyze the metric properties of the current definitions against patient’s perceptionMethods:One-center cross-sectional study in a tertiary care hospital including consecutive patients with a diagnosis of axSpA (and fulfilling the ASAS criteria) were included between February to November 2019. Patient’s perception of remission and LDA was evaluated by a single question. Physician’s perception of remission and LDA was assessed identically. The level of agreement between patients’ perception and the other available definitions was tested by the Prevalence and Bias adjusted Kappa (PABAK). The metric properties Sensitivity (S) and Specificity (Sp) of the available definitions (BASDAI cut-offs, ASDAS disease states, ASAS criteria for partial remission and patient acceptable symptom state), were tested against the patients perspective, as the gold standard.Results:A total of 105 axSpA patients were included. 63,8% were males and 67,6% had radiographic sacroiliitis (Table 1). 21% and 72% of them considered themselves in remission and LDA, respectively. Physician’s perception was 45.7% and 81% for remission and LDA, respectively. The prevalence of the different definitions are shown in Figure 1. The best agreement for patients’s perception of remission was found with a BASDAI <2 + normal CRP (Table 2). This definition was also the most sensitive (S=72,7%) and specific (Sp=83,1%) when taking the patient’s perception as a reference.Table 1.Characteristics of 105 patients with axSpAAll (N:105)Patients in self-defined REM (N:22)Patients in self-defined LDA (N:54)Patients No REM no LDA (N:29)Male, n (%)67 (63,8)18 (81,8)34 (63)15 (51,7)r-axSpA, n (%)71 (67,6)17 (77,3)33 (61,1)21 (72,4)Mean age, years (SD)49 (13)51(15)47 (13)50 (11)Mean AxSpA duration, years (SD)12,2 (13)17,1 (16,2)11,2 (11,7)10,3 (12,3)HLA- B27+, n (%)Data from 10472 (69,2)17/22 (77,3)33/54 (61,1)22/28 (78,6)Periferic arthritis, n (%)34 (32,4)7 (31,8)17 (31,5)10 (45,4)Uveitis, n (%)22 (21)6 (27,3)10 (18,5)6 (20,7)Biological treatment, n (%)43 (41)14 (63,6)19 (35,1)10 (34,5)CRP, mean (SD)3,61 (5,36)2,31 (2,17)2,84 (3,87)6,04 (8,14)ASDAS, mean (SD)1,78 (1,08)0,98 (0,71)1,63 (0,89)2,68 (1,03)BASDAI, mean (SD)3,35 (2,32)1,39 (1,30)3,13 (1,84)5,26 (2,33)BASFI, mean (SD)2,81 (2,45)1,24 (1,37)2,57 (2,00)4,43 (2,92)Table 1.REM: Remission; LDA: Low Disease Activity; SD: Standard Desviation; CRP: C-Reactive Protein IBD: Inflammatory Bowel Disease.Table 2.Agreement between different definitions of remissionASDAS <1,3BASDAI<2+Normal CRPPGA ≤1PhysicianREMPatientREMASAS PR0.53 (0.58)0.59 (0.68)0.76 (0.83)0.22 (0.26)0.39 (0.56)ASDAS <1,30.64 (0.68)0.50 (0.56)0.44 (0.45)0.28 (0.37)BASDAI <2+Normal CRP0.60 (0.69)0.25 (0.28)0.50 (0.62)PGA ≤10.20 (0.24)0.42 (0.62)Physician REM0.20 (0.24)Agreement is presented as Cohen’s Kappa (PABAK: prevalence and bias adjusted kappa).Patient and Physician remission (REM) are based on the single question; ASAS PR:ASAS partial remission; PGA: Patient global assessment.Conclusion:In this real-life population, the evaluation of remission by the patient through a single question was shown to be feasible and to present an acceptable agreement with other definitions.References:[1]Gorlier C, et al. Ann Rheum Dis 2019;78(2):201-8.Fig. 1.REM/LDA: remission/ low disease activity self-defined patient or physician through a simple question. ASDAS <1,3: inactive disease; ASDAS <2,1: low activity; PGA: Patient global assessment; PASS: Patient acceptable symptom state.Acknowledgments:To Ansgar Seyfferth and Alfonso Muriel. To Carlos Sanchez-Piedra, Fernando Alonso and Mercedes Guerra from Sociedad Española de Reumatología, Research Unit.Disclosure of Interests:Marta Valero Grant/research support from: Novartis, Pfizer, Abvie, Speakers bureau: Novartis, Celgene, Javier Bachiller-Corral: None declared, Boris Anthony Blanco Cáceres: None declared, M. Ángeles Blázquez: None declared, Consuelo Díaz-Miguel: None declared, Maria Jesus Garcia Villanueva: None declared, Carmen Larena: None declared, Jose Luis Morell Hita: None declared, Carlos De la Puente Bujidos: None declared, Ana Rodriguez-García: None declared, Mónica Vázquez Díaz: None declared, Anna Moltó Grant/research support from: Pfizer, UCB, Consultant of: Abbvie, BMS, MSD, Novartis, Pfizer, UCB
31
Chinchay, Gerardo Manuel Garcia, and Mercedes Elvira Mere Chávez. "Reseña del libro "Diccionario básico de educación e inclusión lingüística peruana" de Luna García e Sanchez Tafur." Revista Interdisciplinar em Educação e Territorialidade – RIET 1, no. 1 (December 15, 2020): 281–84. http://dx.doi.org/10.30612/riet.v1i1.12847.
Full text
32
Buitrago-Garcia, D., F. Rodriguez, G. Sánchez, and P. Santos-Moreno. "AB1279-HPR A DESCRIPTIVE STUDY RELATED TO THE ADHERENCE BEFORE AND AFTER ENROLLING IN A MULTIDISCIPLINARY EDUCATIONAL PROGRAM." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1930.2–1931. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5549.
Full textAbstract:
Background:Rheumatoid arthritis (RA) is an inflammatory, chronic disease. It leads to deformity and destruction of joints through the erosion of cartilage and bone. Patients with RA report to suffer symptoms in hands, joints, swelling, loss of motion, muscle weakness among others.(1).Centers of excellence in RA have proposed a multidisciplinary model of care with an initial diagnosis, treatment prescription and follow-up with a rheumatologist, periodic consultations with a physiatrist, psychologist, physiotherapist, occupational therapy, nutrition and a patient focused program(2). With this model of care, the patient is seen as a whole, and the expectation is to achieve the best results in the management of RA. However, if the patient does adhere the model becomes ineffective.Objectives:The aim of this to report the attendance to a multidisciplinary model of care for patients with RA that attend to a specialized center in Colombia, before and after enrolling in a educational program.Methods:We performed a descriptive study. Patients enrolled our educational program in July 2019. In our institution patients are followed-up under T2T standards and a multidisciplinary approach, as part of our model of care they have periodic consultations with a rheumatology, physiatrist, psychologist, physiotherapist, occupational therapy and nutrition. We collected sociodemographic data, DAS28, and compare the attendance to each specialty at the beginning and at 6-month follow-up. Descriptive epidemiology was done, we calculated means, and standard deviations for continuous variables and categorical variables were presented as rates. We compared disease activity and adherence at the beginning of the program and after six months of attendance.Results:We included 229 patients; mean age was 59 years ±10; 93% were female. At the beginning of our program, mean DAS28 was 2.57 ± 1.19, from all patients 65% were at remission, 11% at low disease activity 19% at moderate disease activity and, 5% at severe disease activity. Regarding adherence to our model, the medical specialty with the highest attendance was rheumatology (30%) followed by, physical therapy (16%) physiatrist consultation (15%) psychology (13%) and, occupational therapy (11%); the specialty with the lowest attendance was nutrition (8%). After six months of attendance to the educational program, we found an increasing number of patients in remission 67%, low disease activity 15%, moderate disease activity 18%, we did not have patients with severe DA28. Regarding the medical specialties, we found a 3% rise in the attendance to the nutrition consultation and psychology consultation. We did not find statistical association between disease activity and adherence to the model.Conclusion:These results are a clear example of how an educational program is capable of increasing awareness and improving the clinical outcomes and adherence to a multidisciplinary model for approaching RA. As other studies have shown(3), patient education interventions improve adherence to medication and to attendance to health care specialists.References:[1]Santos-Moreno P, Castaneda O, Garro B, Flores D, Sanchez G, Castro C. From the model of integral attention to the creation of centers of excellence in rheumatoid arthritis. Clinical rheumatology. 2015;34 Suppl 1:S71-7.[2]Taibanguay N, Chaiamnuay S, Asavatanabodee P, Narongroeknawin P. Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial. Patient preference and adherence. 2019;13:119-29.Acknowledgments:This project has been funded by a collaboration between the Ministry of Science, Technology and Innovation COLCIENCIAS (contract 746-2018), the Fundación Universitaria de Ciencias de la Salud and Biomab - Center for Rheumatoid ArthritisDisclosure of Interests:Diana Buitrago-Garcia: None declared, Fernando Rodriguez: None declared, GUILLERMO SÁNCHEZ: None declared, Pedro Santos-Moreno Grant/research support from: I have received research grants from Abbvie, Biopas-UCB, Janssen, Novartis, Pfizer., Speakers bureau: I have been a speaker for Abbvie, Biopas-UCB, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi.
33
Matía Polo, Inmaculada. "MUJERES EN LA ESCENA: LA “COMPAÑÍA DE BAILES ESPAÑOLES” DE “LA ARGENTINITA” Y EL ESTRENO DE EL AMOR BRUJO (1933)." RAUDEM. Revista de Estudios de las Mujeres 2 (May 22, 2017): 203. http://dx.doi.org/10.25115/raudem.v2i0.598.
Full textAbstract:
En 1933 Encarnación López Júlvez “La Argentinita”, funda su propia compañía de danza, con la que estrenará El amor brujo (1933), primero en el Teatro Falla de Cádiz y después en el Teatro Español de Madrid. Auspiciada por Ignacio Sánchez Mejías y Federico García Lorca, Encarnación logra trasladar a la escena un cambio de paradigma presente en los círculos de intelectuales de la sociedad urbana, con los que se vincula a raíz de su contacto con Gregorio Martínez Sierra y María Lejárraga y sus actuaciones en el Teatro Eslava de Madrid durante la temporada de 1919-1920. Palabras clave: Danza Española, “La Argentinita”, Martínez Sierra, El amor brujo, Pilar López. Women in the Scene: the “Company of Spanish Dances” of “La Argentinita” and the Premiere of El amor brujo (1933) Abstract: Encarnación López Júlvez “Argentinita”, founded her own dance company “Compañía de Bailes españoles” in 1933, with which she will premiere El amor brujo (1933), in Teatro Falla (Cádiz) and Teatro Español (Madrid). Supported by Ignacio Sanchez Mejias and Federico García Lorca, Encarnación transfers a paradigm present in the intellectual circles of urban society to the theatrical scene, with which she is linked because of her relation with Gregorio Martinez Sierra and Maria Lejárraga, and her performances at the Teatro Eslava (Madrid) during the 1919-1920 season.Key words: Spanish Dance, “La Argentinita”, Martínez Sierra, Amor Brujo, Pilar López
34
ARROYO, FRANK. "A new species of Magnolia (Magnoliaceae) from central Peru." Phytotaxa 167, no. 2 (May 9, 2014): 220. http://dx.doi.org/10.11646/phytotaxa.167.2.14.
Full textAbstract:
Peruvian species of Magnolia were not included in major treatments of the Peruvian flora until the last decade, following revisions of Dugandiodendron and Talauma for the Neotropics published by Lozano-Contreras in 1994 (Pennington et al. 2004, Ulloa et al. 2004) when M. amazonica (Ducke, 1925: 11) Govaerts (1996: 25) and M. rimachii, (Lozano, 1994: 105) Govaerts (1996: 39), two lowland Amazonian species, were included. Subsequently, new species of Magnolia were described from the eastern humid montane and lowland forests in northern and central Peru (Dillon & Sanchez 2009, Vázquez-García et al. 2012). The new species reported here is described for the humid forests of the eastern Andean slopes of central Peru. Following the classification proposed by Figlar & Nooteboom (2004), this species belong to genus Magnolia subgenus Magnolia section Talauma subsection Talauma because of stipule adnation to petioles, circumscissile dehiscence of fruits and absence of a filamentous appendage in the stamen connective.
35
Valverde, Jenny, and Francisco Caicedo. "CÁLCULO DE LAS BETAS DEL CAPITAL ASSET PRICING MODEL COMO INDICADOR DE RENTABILIDAD DE LAS EMPRESAS VINCULADAS A LA BOLSA DE VALORES DE ECUADOR." Universidad Ciencia y Tecnología 24, no. 107 (December 25, 2020): 79–87. http://dx.doi.org/10.47460/uct.v24i107.417.
Full textAbstract:
El riesgo al invertir en títulos-valeres pertenecientes al mercado de capitales no solo depende de los resultados de los emisores, sino, del entorno económico. Bajo este contexto, el objetivo del estudio fue calcular las betas mediante la aplicación del Capital Asset Princing Model (CAPM), para conocer la influencia rentable de las empresas vinculadas a la Bolsa de Valores de Ecuador. La muestra fue de 35 empresas tenedoras de acciones durante el periodo 2014-2019. Lainvestigación se desarrolló bajo un enfoque cuantitativo, mediante un alcance correlacional entre las variables riesgo sistemático y la rentabilidad. Los resultados evidenciaron que utilizar el riesgo sistemático no es considerado como un modelo de valuación de activos financieros fuertes, debido a que, trabaja bajo supuestos. Se concluye que en los emisores de acciones analizados no incide el beta en la rentabilidad ofertada por las empresas vinculadas a la Bolsa de Valores ecuatoriana.
Palabras Clave: mercado de valores de Ecuador, modelo de valuación de activos de capital (CAPM), riesgo sistemático, rentabilidad.
Referencias
[1]F. J. Riofrio, “Análisis comparativo del mercado de valores: Ecuador, Colombia, Perú, y propuesta de medidas para el desarrollo del caso ecuatoriano.,” Universidad Internacional del Ecuador, 2019.
[2]C. Albuja, “Integración del Mercado de Valores en Ecuador, factibilidad del proyecto,” Pontificia Universidad Católica del Ecuador, 2013.}
[3]E. Quiroga, “Eficiencia en los mercados financieros y predicción de precios de los activos,” Ciencias Adm.,vol. 10, p. 11, 2017, [En línea]. Disponible en: http://www.redalyc.org/articulo.oa?id=511653854005. [Último acceso: 2020].
[4]J. B. Duarte Duarte, L. H. Talero Sarmiento, y K. J. Sierra Suárez, “Evaluación del efecto de la psicología del inversionista en un mercado bursátil artificialmediante su grado de eficiencia,” Contaduria y Adm., vol. 62, no. 4, pp. 1345–1360, 2017, doi: 10.1016/j.cya.2017.06.007.
[5]F. Rubio, “Capital Asset Pricing Model (Capm) Y Arbitrage Pricing Theory (Apt): Una Nota Técnica,”Recuper., January 2004, p. 4, 2004, doi: http://econwpa.repec. org/eps/fin/papers/0402/0402007. pdf.
[6]W. Sharpe, “Capital Asset Prices A Theory of Market Equilibrium under Conditions of Risk-convertido ES,”Wiley-Blackwell, 1964.
[7]O. Mejía, “Discusión sobre la teoría moderna del portafolio. Aplicación de la internacionalización del portafolio, incluyendo el caso colombiano,” Estud. Gerenciales, pp. 103–116, 2004.
[8]E. Sansores, “El modelo de valuación de activos de capital aplicado a mercados fi nancieros emergentes,” Contaduria y Adm., no. 226, pp. 93–111, 2008.
[9]A. Sanchez, “La Rentabilidad Economica Y Financiera de la Gran Empresa Española,” Rev. Española Financ. y Contab., vol. XXIV N° 78, p. 159 179, 1994, [En línea]. Disponible en: https://www.mendeley.com/viewer/?fileId=4725a92a-52e8-75a5-78c5-00e3476e79ab&documentId=414ff01c-9b08-3eba-a6a4-beb-38dd799f7. [Último acceso: 2020].
[10]F. Garcia, J. Gonzalez, G. Rueda, y J. Oliver, “Characterization of capital markets of Latin America, 2000-2016: A comparative analysis,” Espacios, vol. 39,no. 50, p. 9, 2018.
[11]B. Tocabens, “Definiciones acerca del riesgo y sus implicaciones,” Rev. Cubana Hig. Epidemiol., vol. 49, no. 3, pp. 470–481, 2011.
[12]C. Martínez, J. Ledesma, y A. Russo, “Particularidades del Modelo de Fijción de Precios de Activos de Capital (CAPM) en Mercados Emergentes,” 2013. [En línea]. Disponible en: www.unq.edu.ar. [Último acceso: 2020].
[13]A. Támara, I. Chica, y A. Montiel, “Metodología de cálculo del beta: Beta de los activos, beta apalancado y beta corregido por cash,” Espacios, vol. 38, no. 34, 2017, [En línea]. Disponible en: https://www.revistaespacios.com/a17v38n34/a17v38n34p15.pdf. [Último acceso: 2020].
[14]C. Martínez, J. Ledesma, y A. Russo, “Calculating beta models to apply in Capital Asset Pricing Model: The case of Argentina,” Estud. Gerenciales,vol. 30, no. 131, pp. 200–208, 2014, doi: 10.1016/j.estger. 2014.03.002.
[15]I. Conte, “La inestabilidad de la β como medidor del riesgo sistemático y sus implicaciones en el modelo de valoración CAPM.,” Universidad Pontificia Comillas, 2014.
[16]R. Hérnandez, C. Férnandez, y M. Baptista, Metodología de la investigación, Mc Graw Hi. México D.F., 2010.
[17]E. Cabezas, D. Andrade, y J. Torres, Introducción a la Metdología de la Investigación Científica, David Andr., vol. 66. 2018.
[18]Banco Central del Ecuador, “Índices Bursátiles”, [En línea]. Disponible en: https://www.bce.fin.ec/index.php/component/k2/item/149-indices-burs%C3%A1tiles, 2019. [Último acceso: 2020].
36
Garcia-Sancho, Miguel, and Karin Knorr Cetina. "“These Were Not Boring Meetings”: Miguel García-Sancho Talks with Karin Knorr Cetina." Engaging Science, Technology, and Society 4 (July 12, 2018): 246. http://dx.doi.org/10.17351/ests2018.239.
Full textAbstract:
In this interview, Karin Knorr Cetina evokes the first Annual Meeting of the Society for Social Studies of Science at Cornell University in 1976 as a foundational moment for science and technology studies (STS). This conference consolidated a new approach to the study of science based on the anthropological observation of scientists at work in the laboratory. Knorr Cetina argues that, despite geographically cementing in the United States, this approach originated mainly through the work of European scholars. The years that followed the Cornell meeting were marked by intense debates between the defenders of this anthropological approach and other scholars more focused on ideas than on scientific practice. Knorr Cetina describes these debates as “bloodbaths” and recalls having first coined the term “constructivist” as applied to science studies in 1977. For Knorr Cetina, STS is now shifting its attention from the production to the consumption of technoscientific knowledge. Her current interest in the financial markets and other forms of screen technologies is an example of this transition. She argues that STS needs to overcome its current fragmentation and emphasis in isolated case studies. The establishment of basic research centers with the financial resources to develop collective and long-term programs would help scholars to expand their horizons. In his following reflection, Miguel García-Sancho explores the connections between STS and travel in both a sense of intellectual shift and a more mundane meaning of physical movement.
37
Castilla Urbano, Francisco. "Pasión, razón y política en la tragedia Don Sancho García, de José Cadalso." Bulletin of Spanish Studies 96, no. 4 (April 12, 2019): 573–96. http://dx.doi.org/10.1080/14753820.2019.1596643.
Full text
38
Avril, Joseph. "Synodicon Hispanum, sous la direction d ' Antonio García y García, V. Extremadura: Badajoz, Coria-Cáceres y Plasencia, hg. von Bernardo Alonso Rodriguez, Francisco Cantelar Rodriguez, Antonio García y García, Jose Luis Martin Martin, Juan Candido Matías Vicente, Carmen Perez-Coca y Sanchez-Mata." Zeitschrift der Savigny-Stiftung für Rechtsgeschichte: Kanonistische Abteilung 79, no. 1 (August 1, 1993): 505–6. http://dx.doi.org/10.7767/zrgka.1993.79.1.505.
Full text
39
Alonso, M. T., J. Alvarez, M. Montero, A. Sanchez, and J. García-Sancho. "Agonist-induced Ca2+ influx into human platelets is secondary to the emptying of intracellular Ca2+ stores." Biochemical Journal 280, no. 3 (December 15, 1991): 783–89. http://dx.doi.org/10.1042/bj2800783.
Full textAbstract:
We have studied the relation between the filling state of the intracellular Ca2+ stores and the plasma-membrane permeability to Mn2+, used here as a Ca2+ surrogate for Ca2+ channels. Emptying of the intracellular Ca2+ stores either by incubation in Ca(2+)-free medium or by treatment with low concentrations of the Ca2+ ionophore ionomycin accelerated the influx of Mn2+. Refilling of the Ca2+ stores by incubation in Ca(2+)-containing medium restores low Mn2+ permeability. This Ca(2+)-store-regulated permeability was inhibited by Ni2+ and by cytochrome P-450 inhibitors. Stimulation of platelets with thrombin produced Ca2+ release from the intracellular stores, which was followed, after a temperature-dependent lag (2 s at 37 degrees C; 5 s at 18 degrees C), by an acceleration of Mn2+ influx. Cytochrome P-450 inhibitors prevented the thrombin-induced Mn2+ influx, with little effect on the Ca2+ mobilization from the intracellular stores. Ki values were similar to those estimated for inhibition of the store-regulated permeability in non-stimulated platelets. Similar results were found in platelets stimulated by platelet-activating factor or by ADP. We propose that agonist-induced Ca2+ (Mn2+) influx in platelets is secondary to the emptying of the intracellular Ca2+ stores. The activation of the plasma-membrane Ca2+ (Mn2+) pathway may take place by a mechanism involving microsomal cytochrome P-450, similar to that described previously in thymocytes [Alvarez, Montero & García-Sancho (1991) Biochem. J. 274, 193-197] and neutrophils [Montero, Alvarez & García-Sancho (1991) Biochem. J. 277, 73-79].
40
Stevens, H. "Miguel Garcia-Sancho, Biology, Computing, and the History of Molecular Sequencing: From Proteins to DNA, 1945-2000." Social History of Medicine 27, no. 2 (January 14, 2014): 397–98. http://dx.doi.org/10.1093/shm/hkt110.
Full text
41
Ансарін Алі Акбар and Джаваді Шалал. "Маскований семантичний/ асоціативний та перекладний праймінг у різних мовах." East European Journal of Psycholinguistics 5, no. 1 (June 30, 2018): 7–15. http://dx.doi.org/10.29038/eejpl.2018.5.1.ans.
Full textAbstract:
Статтю присвячено спробі дослідити двомовний ментальний лексикон. Головне питання дослідження – встановити, чи персько-англійські білінгви можуть досягнути ефекту семантичного / асоціативного або перекладацького праймінгу. Для відповіді на це питання було застосовано масковану праймінгову парадигму як техніку, що відображає автоматичні когнітивні процеси, що тривають під час семантичної обробки, а не стратегічного використання прайму. Із метою вирішення лексичного завдання було сформовано чотири типи цільових пар праймінгу (перекладацькі еквіваленти, семантично подібні, асоціативно та семантично пов’язані пари). Загалом у дослідженні взяло участь 85 персько-англійських білінгвів. Хоча ефекту праймінгу не було виявлено для перших трьох груп, респонденти із семантично пов’язаних пар (найміцніше пов’язаних слів) відповіли приблизно на 29 мс швидше. Результати засвідчили, що білінгви мають спільні уявлення для асоціативних семантично пов’язаних слів. Отже, навчання новим словам другої мови, шляхом поєднання їх із асоціативно пов’язаними словами першої мови, може привести до кращих результатів.
Література
References
Balota, D. A., & Lorch, R. F. (1986). Depth of automatic spreading activation: Mediated priming effects in pronunciation but not in lexical decision. Journal of Experimental Psychology: Learning, Memory, Cognition, 12, 336–345.
Chiarello, C., Burgess, C., Richards, L., & Pollock, A. (1990). Semantic and associative priming in the cerebral hemispheres: Some words do, some words don’t…Sometimes, some places. Brain and Language, 38, 75–104.
Collins, A. M., & Loftus, E. F. (1975). A spreading activation theory of semantic priming. Psychological Review, 82, 407–428.
Coltheart, M. (1981). The MRC Psycholinguistic Database. Quarterly Journal of Experimental Psychology, 33A, 497–505.
Costa, A., Colome, A., & Caramazza, A. (2000). Lexical access in speech production: The bilingual case. Psicologica, 21, 403–437.
de Groot, A. M. B., & Nas, G. L. (1991). Lexical representation of cognates and non-cognates in compound bilinguals. Journal of Memory and Language, 30, 90–123.
Dijkstra, A. F. J., & Van Heuven, W. J. B. (2002). The architecture of the bilingual word recognition system: From identification to decision. Bilingualism: Language and Cognition, 5(3), 175-197.
Duyck, W. (2005). Translation and associative priming with cross-lingual pseudohomophones: Evidence for nonselective phonological activation in bilinguals. Journal of Experimental Psychology: Learning, Memory, and Cognition, 31, 1340–1359.
Fischler, I. (1977). Semantic facilitation without association in a lexical decision task. Memory & Cognition, 5, 335–339.
Forster, K. I., & Davis, C. (1984). Repetition priming and frequency attenuation in lexical access. Journal of Experimental Psychology: Learning, Memory, and Cognition, 10, 680–698.
Forster, K. I., & Forster, J. C. (2003). DMDX: A Windows display program with millisecond accuracy. Behavior Research Methods, Instruments, & Computers, 35(1), 116–124.
Fotovatnia, Z., & Taleb, F. (2012). Masked noncognate priming across Farsi and English. Journal of Teaching Language Skills, 4(1), 25–48.
French, R. M., & Jacquet, M. (2004). Understanding bilingual memory. Trends in Cognitive Science, 8, 87–93.
Grainger, J., & Frenck-Mestre, C. (1998). Masked priming by translation equivalents in proficient bilinguals. Language and Cognitive Processes, 13(6), 601–623.
Jiang, N., & Forster, K. I. (2001). Cross-language priming asymmetries in lexical decision and episodic recognition. Journal of Memory and Language, 44(1), 32–51.
Kotz, S. A. (2001). Neurolinguistic evidence for bilingual language representation: A comparison of reaction times and event-related brain potentials. Bilingualism: Language and Cognition, 4, 143–154.
Kroll, J. F., & Stewart, E. (1994). Category interference in translation and picture naming: Evidence for asymmetric connections between bilingual memory representations. Journal of Memory and Language, 33,149–174.
Lupker, S. J. (1984). Semantic priming without association: A second look. Journal of Verbal Learning and Verbal Behavior, 23, 709–733.
Perea, M., Duñabeitia, J. A., & Carreiras, M. (2008). Masked associative/semantic priming effects across languages with highly proficient bilinguals. Journal of Memory and Language, 58, 916–930.
Perea, M., & Rosa, E. (2002). The effects of associative and semantic priming in the lexical decision task. Psychological Research, 66, 180–194.
Samani, R., & Sharifian, F. (1997). Cross-language hierarchical spreading of activation. In Sharifian, F. (ed.), Proceedings of the Conference on Language, Cognition, and Interpretation (pp. 11–23). Isfahan: IAU Press.
Sanchez-Casas, R. M., Davis, C. W., & Garcia-Albea, J. E. (1992). Bilingual lexical processing: Exploring the cognate/non-cognate distinction. European Journal of Cognitive Psychology Special Issue: Multilingual Community, 4(4), 293–310.
Williams, J. N. (1994). The relationship between word meanings in the first and second language: Evidence for a common, but restricted, semantic code. European Journal of Psychology, 6, 195–220.
42
Martín-Varillas, J. L., V. Calvo-Río, L. Sanchez-Bilbao, I. González-Mazón, I. Torre-Salaberri, Á. García Martos, A. Sanchez-Andrade, et al. "THU0311 CERTOLIZUMAB THERAPY IN REFRACTORY UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMID). MULTICENTER STUDY OF 39 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 384.2–385. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6367.
Full textAbstract:
Background:Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use of other anti-TNF drugs such as Certolizumab Pegol (CZP).Objectives:To evaluate the efficacy and safety of CZP in uveitis secondary to Immune-Mediated Inflammatory Diseases (IMID).Methods:Multicenter study of 39 patients with uveitis due to IMID refractory to glucocorticoids and conventional immunosuppressants. Efficacy of CZP was evaluated with the following ocular parameters: best corrected visual acuity (BCVA), anterior chamber cells, macular thickness and presence of retinal vasculitis. Efficacy of CZP was compared between baseline, 1st week, 1st and 6th month, and 1st and 2nd year. Statistical analysis was performed with the STATISTICA software (Statsoft Inc. Tulsa, Oklahoma, USA).Results:39 patients/56 affected eyes (18 men/21 women) with a mean age of 40.5±11.9 years were studied. IMIDs included were: spondyloarthritis (n=17), psoriatic arthritis (6), Crohn (3), JIA (2), Behçet (2), reactive arthritis (2), rheumatoid arthritis (1), relapsing polychondritis (1), pars planitis (1), Birdshot (1) and idiopathic uveitis (3). Uveitis pattern was as follows: anterior (n=30), posterior (4), panuveitis (3) and intermediate (2).Previous CZP, patients received: oral prednisone (n=18) methylprednisolone bolus (1), methotrexate (22), azathioprine (10), cyclosporine (4), leflunomide (2), mycophenolate mofetil (2) and cyclophosphamide (1). 77% of patients had received previous biological therapy, with a mean of 1.6±1.2 biological drugs per patient. Gestational desire was the reason for prescribing CZP in 8 patients. CZP was administered in monotherapy in 16 patients and in the remaining 23 patients combined with conventional immunosuppressants.After a median follow-up of 24 [6-36] months, most of the ocular variables analysed showed a rapid and significantly sustained improvement (Table). CZP was discontinued in 11 patients for the following reasons: remission (n=1), insufficient response of ocular symptoms (n=1) and limited response of extraocular manifestations (n=9). No serious adverse effects were reported.Conclusion:CZP seems to be effective and safe in patients with refractory uveitis due to IMID.TableBaseline1stweek1stMonth6thMonth1styear2ndyearBCVA (mean±SD)0.77±0.290.77±0.30*0.82±0.29*0.85±0.26*0.86±0.27*0.88±0.23*Tyndall (median [IQR])0 [0-2]0 [0-2]0 [0-1]*0 [0-0]*0 [0-0]*0 [0-0]*OCT (mean±SD)355±61.5-284.1±40.4*-224.8±121.1*-Retinal Vasculitis (eyes affected, %)2 (3.6)0 (0)0 (0)0 (0)0 (0)0 (0)*p<0.05Disclosure of Interests:José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Vanesa Calvo-Río Grant/research support from: MSD and Roche, Speakers bureau: AbbVie, Lilly, Celgene, Grünenthal, UCB Pharma, Lara Sanchez-Bilbao Grant/research support from: Pfizer, Iñigo González-Mazón: None declared, Ignacio Torre-Salaberri: None declared, Álvaro García Martos: None declared, Amalia Sanchez-Andrade: None declared, Ángel García-Aparicio: None declared, JR De Dios-Jiménez Aberásturi: None declared, ANA URRUTICOECHEA-ARANA: None declared, Olga Maíz: None declared, Raul Veroz Gonzalez: None declared, Andrea García-Valle: None declared, Sergio Rodríguez Montero: None declared, Roberto Miguélez: None declared, Vega Jovani: None declared, Marisa Hernández-Garfella: None declared, Arantxa Conesa: None declared, Olga Martínez González: None declared, Paula Rubio Muñoz: None declared, Belén Atienza-Mateo: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD
43
Sene, Glaucia Malerba, and Nayara Amado. "ROMERO, Margarita Sanchéz, GARCIA, Eva Alarcón, JIMÉNEZ, Gonzalo Aranda (ed.). Children, spaces and identity. United Kington: Oxbow Books, 2015, 364p." Habitus 16, no. 1 (June 29, 2018): 177. http://dx.doi.org/10.18224/hab.v16i1.6508.
Full textAbstract:
No final da década de 1980, começaram a surgir os primeiros trabalhos sobre arqueologia da infância (Lillehammer, 1989, BAXTER, 2006) como um desdobramento da avalanche teórica promovida pelas arqueologias de gênero e feminista. Deste então, foram contínuas, mas discretas as publicações sobre o tema com enfoque arqueológico.Em 2015, surge a publicação Children, spaces and identity, reavivando as discussões sobre gênero e idade com ênfase na infância, aqui representada por diferentes faixas etárias até a adolescência. Concentrando experiências e estudos de caso muito diversificados sobre o tema, o livro, organizado pelos autores supracitados, vem para acrescentar novas reflexões sobre o assunto, ainda que os contextos analisados sejam predominantemente os europeus. O livro foi subdividido em três partes, que tratam respectivamente sobre (I) Crianças, espaços e identidade, (II) Brincando, vivendo e aprendendo e (III) Espaço, corpo e mente: crianças em contextos funerários, totalizando vinte e cinco artigos científicos de diferentes autores.
44
Domning, Daryl P., and Orangel A. Aguilera. "Fossil Sirenia of the West Atlantic and Caribbean region. VIII.Nanosiren garciae, gen. et sp. nov. andNanosiren sanchezi, sp. nov." Journal of Vertebrate Paleontology 28, no. 2 (June 12, 2008): 479–500. http://dx.doi.org/10.1671/0272-4634(2008)28[479:fsotwa]2.0.co;2.
Full text
45
Isnardi, C. A., E. E. Civit De Garignani, A. García Ciccarelli, J. Sanchez Alcover, R. Garcia Salinas, S. Magri, E. Albiero, et al. "AB0214 SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1133–34. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1399.
Full textAbstract:
Background:Golimumab is a human monoclonal antibody directed against TNFα in its soluble and transmembrane forms. It can be used subcutaneously or intravenously and has shown efficacy for use in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).Objectives:The aim of this study was to evaluate the efficacy, safety, and cumulative survival of golimumab in patients with RA, PsA and AS from different rheumatology centers in Argentina.Methods:We performed a longitudinal study of consecutive adults with RA (ACR/EULAR 2010 criteria), PsA (CASPAR criteria) and AS (ASAS 2009 criteria), who have started treatment with subcutaneous or intravenous golimumab according to medical indication in each center. Data was obtained by review of medical records. Sociodemographic and clinical data, musculoskeletal manifestations, comorbidities, previous treatments were recorded. In reference to golimumab treatment, start date, route of administration and concomitant treatments were identified. Disease activity was assessed using DAS28 for RA patients, DAPSA and MDA for PsA and BASDAI for AS. The presence of adverse events (AE) was recorded. If golimumab was stopped, date and cause was documented. Patients were followed up until golimumab discontinuation, loss of follow-up, or study completion (November 30, 2020). Statistical analysis: Chi2 test or Fischer exact test and T test or Mann Whitney and ANOVA or Kruskal Wallis, as appropriate. The incidence of EA was assessed in events every 100 patient/year. Kaplan-Meier curves and log Rank analysis. Cox proportional regression.Results:One hundred eighty two patients were included, 116 with a diagnosis of RA, 30 with PsA and 36 with AS. Most of them (70.9%) were female with a median (m) age of 55 years (IQR 43.8-64) and m disease duration of 7 years (IQR 4-12.7) at treatment initiation. Al least one prior biological DMARD or a small molecule was received by 63 patients (34.6%). The most frequent indication cause was conventional DMARD failure. In 94.8% of the patients Golimumab was administered subcutaneously, and in 80.8% in association with conventional DMARDs, the most frequently used was methotrexate. Total follow-up was 318.1 patients/year.Golimumab treatment showed clinical improvement in all three groups of patients. In RA patients DAS28 significantly decreased during the first 12 months of follow-up, m 5.9 (IQR 4.9-6.6) at baseline, 3.8 (IQR 2.6-4.6) at 6 months and 2.8 (IQR 2.1-3.6) at 12 months, p <0.0001. In PsA, m DAPSA-ESR value was 32.2 (IQR 24.2-47.7), 10.1 (IQR 5.8-18.3) and 11.2 (IQR 3.4-24) at baseline, 6 and 12 months, respectably (p <0.0001). In AS, m BASDAI was 6.2 (IQR 4.8-7.3), 2.8 (IQR 1.7-4.1) and 2.2 (IQR 1.1-3.2), at baseline, 6 and 12 months respectively (p <0.0001).The incidence of adverse events was 6.6 per 100 patients/year, being infections the most frequents ones. During follow-up, 50 patients (27.5%) discontinued golimumab, the most frequent cause was treatment failure (68%), followed by lack of health insurance (16%) and adverse events (10%). Golimumab persistence was 79% and 57.6% at 12 and 24 months, respectively. Treatment survival was 50.2 months (95% CI 44.4-55.9). Patients who had received prior treatment with biological DMARDs or small molecules showed lower survival (Figure 1). In the multivariate analysis, adjusting for age, sex and disease duration, those patients showed twice the risk of suspending treatment (HR 2.01, 95% CI 1.1-3.7).Figure 1.Golimumab survival according to prior b-DMARD o small molecule treatment.Conclusion:Golimumab treatment in real life patients in Argentina has shown good efficacy and safety. Drug survival was over 4 years and almost 80% were still using golimumab after one year. Prior treatment with other b-DMARDs o small molecules was associated with lower treatment survival.Disclosure of Interests:Carolina Ayelen Isnardi Speakers bureau: Bristol Myers Squibb, Janssen, Grant/research support from: Pfizer, Emma Estela Civit De Garignani Speakers bureau: Abbvie, Novartis, Agustín García Ciccarelli Speakers bureau: Janssen, Novartis, Consultant of: Novartis, Grant/research support from: Janssen, Novartis, Jimena Sanchez Alcover: None declared, Rodrigo Garcia Salinas Speakers bureau: Abbvie, AMGEN, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen Cilag, Montpellier-UCB, Novartis, Roche – Genentech, Sanofi, Merck Serono., Sebastian Magri Speakers bureau: Abbvie, AMGEN, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen Cilag, Montpellier-UCB, Novartis, Roche – Genentech, Sanofi, Merck Serono., Eduardo Albiero Consultant of: Janssen, Carla Gobbi Speakers bureau: Pfizer, Consultant of: Pfizer, Janssen, Edson Velozo Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: Abbvie, Janssen, Novartis, Grant/research support from: Janssen, Novartis, Pfizer, Enrique Soriano Speakers bureau: AbbVie, Novartis, Bristol MS, Novartis, Eli Lilly, Genzyme, Pfizer, Amgen, and Roche, Consultant of: Novartis, AbbVie, Pfizer, Eli Lilly, Sanofi, Sandoz, Amgen., Grant/research support from: Roche, Novartis, AbbVie, Glaxo Smith Kline, BMS, Martín Brom: None declared, Johana Zacariaz Grant/research support from: Bristol Myers Squibb, Ingrid Strusberg Speakers bureau: Gema Biotech SAU, BMS, Abbvie, Consultant of: Gema Biotech SAU, Abbvie, Janssen, Grant/research support from: Abbvie, Lilly, Galápagos, Servier, GSK, Merck Serono, Marcos BARAVALLE Speakers bureau: Montepellier, Consultant of: Abbvie, Janssen, Grant/research support from: Abbvie, Lilly, Galápagos, Servier, GSK, Merck Serono, Sol Castaños Speakers bureau: Abbvie, Lilly, Galápagos, Servier, GSK, Merck Serono, Liliana Morales Speakers bureau: Lilly, Consultant of: Janssen, Grant/research support from: Abbvie, Lilly, Galápagos, Servier, GSK, Merck Serono, Sergio Paira: None declared, Romina Calvo: None declared, Alberto Ortiz: None declared, Rodolfo Perez Alamino Speakers bureau: Pfizer, Abbvie, Amgen, Bristol-Myers-Squibb, Lilly, Janssen, Novartis, Hernan Maldonado Ficco Speakers bureau: Pfizer, Abbvie, Jansen, Novartis, Bago, Bristol, Eli Lilly., Consultant of: Pfizer, Abbvie, Novartis, Jansen, Bago, Eli Lilly., Gustavo Citera Speakers bureau: Abbvie, BMS, Lilly, Jansen, Gema, Pfizer, Roche, Grant/research support from: Pfizer
46
Suárez Arévalo, Jesús, and Manuel García Luque. "El conde de Oñate y la remodelación de la capilla de Santiago en la colegiata de San Hipólito de Córdoba." Archivo Español de Arte 93, no. 370 (May 29, 2020): 131. http://dx.doi.org/10.3989/aearte.2020.09.
Full textAbstract:
Este artículo analiza la reforma de la capilla de Santiago de la colegiata de San Hipólito de Córdoba, sufragada por el conde de Oñate y duque consorte de Baena y Sessa a mediados del siglo XVIII. A través de fuentes inéditas se documenta el traslado de las tumbas de los fundadores, el mariscal Diego Fernández de Córdoba y su primera esposa Sancha García de Rojas, y la realización de un nuevo retablo por Teodosio Sánchez, presidido por una escultura de Santiago tallada por Pedro Duque Cornejo. El caso pone de relieve las dificultades que tuvo que afrontar el clero colegial para que el noble asumiera sus obligaciones de patronato.
47
Câmara, Benedita, Piet van Cruyningen, Xavier Cussó Segura, Sara Torregrosa Hetland, Miguel Cabo, Santiago M. López-García, Samuel Garrido, et al. "Book reviews - Crítica de libros - Crítica de livros (Historia Agraria, 77)." Historia Agraria Revista de agricultura e historia rural, no. 77 (February 19, 2019): 203–55. http://dx.doi.org/10.26882/histagrar.077r08b.
Full textAbstract:
Book reviews Dulce Freire and Pedro Lains (Eds.). An Agrarian History of Portugal, 1000-2000: Economic Development on the European Frontier. Leiden/Boston, Brill, 2017, 347 pp. Benedita Câmara Annie Antoine (Ed.). Agricultural Specialisation and Rural Patterns of Development. Turnhout, Brepols, 2016, 303 pp. Piet van Cruyningen Guido Alfani and Cormac Ó Gráda (Eds.). Famine in European History. Cambridge, Cambridge University Press, 2017, 325 pp. Xavier Cussó Segura Marc Badia-Miró, Vicente Pinilla and Henry Willebald (Eds.). Natural Resources and Economic Growth: Learning from History. Abingdon/New York, Routledge, 2015, 374 pp. Sara Torregrosa Hetland Niccolò Mignemi. Coopératives et mondes agricoles: France et Italie (1880-1950). Rennes, Presses Universitaires de Rennes, 2017, 337 pp. Miguel Cabo Domingo Gallego, Luis Germán y Vicente Pinilla (Eds.). Estudios sobre el desarrollo económico español. Dedicados al profesor Eloy Fernández Clemente. Zaragoza, Prensas de la Universidad de Zaragoza, 2016, 408 pp. Santiago M. López-García Ricard Garcia Orallo. La terra a subhasta. Crisi, endeutament i despossessió al món rural català de finals del segle xix. Barcelona, Publicacions de l’Abadia de Montserrat, 2015, 644 pp. Samuel Garrido Lluís Serrano Jiménez. Tancar la terra: Pràctiques de propietat i dinàmiques socials (Catalunya, 1850-1910). Girona, Documenta Universitaria/Associació d’Història Rural de les Comarques Gironines, 2016, 324 pp. Antonio Miguel Linares Luján Jordi Planas Maresma. Francesc Torras Sayol (1868-1936): Un propietari conservador al capdavant de l’acció cooperativa. Barcelona/Valls, Fundació Roca i Galès/Cossetània Edicions, 2016, 102 pp. Josep M. Pons-Altés Josep Joan Mateu González. Enginyers i regants: El Canal d’Aragó i Catalunya (1896-1940). Lleida, Universitat de Lleida/Patronat Josep Lladonosa, 2017, 256 pp. Carles Sanchis Ibor Gladys Karina Sánchez Juárez. Los pequeños cafeticultores de Chiapas: Organización y resistencia frente al mercado. Tuxtla Gutiérrez, CESMECA-UNICACH, 2015, 225 pp. Albert Folch David Sowell. Medicine on the Periphery: Public Health in Yucatán, Mexico, 1870-1960. Lanham, Lexington Books, 2015, 205 pp. Mikel Astrain Pablo Alonso González. El Antipatrimonio: Fetichismo y dominación en Maragatería. Madrid, Centro Superior de Investigaciones Científicas, 2017, 326 pp. Guadalupe Jiménez Esquinas Marcel Mazoyer y Laurence Roudart. Historia de las agriculturas del mundo: Del Neolítico a la crisis contemporánea . Oviedo, KRK, 2016, 1.073 pp. Cristóbal Gómez Benito
48
Abir-Am, Pnina Geraldine. "García-Sancho. 2012. Biology, Computing, and the History of Molecular Sequencing; From Proteins to DNA, 1945-2000." THEORIA. An International Journal for Theory, History and Foundations of Science 29, no. 3 (October 7, 2014): 433. http://dx.doi.org/10.1387/theoria.12679.
Full text
49
Yi, Doogab. "Miguel García-Sancho: Biology, computing, and the history of molecular sequencing: from proteins to DNA, 1945–2000." History and Philosophy of the Life Sciences 36, no. 1 (July 18, 2014): 131–32. http://dx.doi.org/10.1007/s40656-014-0011-4.
Full text
50
García, Idalia. "La cultura del libro en la Nueva España." Revista Complutense de Historia de América 45 (June 14, 2019): 15–19. http://dx.doi.org/10.5209/rcha.64684.
Full textAbstract:
Desde finales del siglo XIX, algunos eruditos y bibliófilos (Harrisse, Zarco del Valle, Sancho Rayón y García Icazbalceta) comenzaron a interesarse por los primeros impresos de America producidos entre 1539 y 1600. La capital novohispana fue el lugar donde se instaló la primera prensa tipográfica de todo el continente, justo dieciocho años después de la conquista de Tenochtitlán y la fundación de la capital virreinal. A partir de este momento, el estudio, registro, descripción y puntual recuento de los ejemplares conservados ha generado atención, debate y, sin duda, bastantes pasiones. La consideración de tal producción bibliográfica como “incunables americanos” o simples “impresos mexicanos del siglo XVI”, ha confrontado a varios estudiosos desde principios del siglo XX hasta la fecha como para generar un proyecto digital que proyecta su importancia y conjunta esfuerzos de algunas bibliotecas internacionales.